Peptide LibraryGlow (GHK-Cu / BPC-157 / TB-500)
Also known as: GHK-Cu + BPC-157 + TB-500, GLOW blend
Glow (GHK-Cu / BPC-157 / TB-500), also called GHK-Cu + BPC-157 + TB-500 or GLOW blend, is a regenerative-cosmetic blend in the Multi-Mechanism Repair class. Glow is a compounded blend rather than a single compound, combining GHK-Cu, BPC-157 and TB-500.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- Varies
- Half-life
- Varies by component
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Extracellular matrixAngiogenic pathways (component-dependent)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 41
- Listed offers
- 87
- Median price per mg (peptide vials)
- $1.43/mg
- Typical $1.10–$1.80/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials38 vendors · median $1.43/mg
- Sprays, route not stated2 vendors · $1.07–$1.54/mg
- Capsules4 vendors · $3.24/mg
- Topicals3 vendors
- Other forms1 vendor
Research summary
Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Glow (GHK-Cu / BPC-157 / TB-500) profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Glow (GHK-Cu / BPC-157 / TB-500) dosage: no established human dose
Glow, a blend of GHK-Cu, BPC-157 and TB-500 in one vial, has no established human dosage. No human study has tested this blend, and none of its three components has an established human dose given by injection. GHK-Cu's human studies are topical, and BPC-157 and TB-500 have only small or unfinished human studies.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Glow is a vendor blend, not a studied product. Each component has its own, mostly preclinical, literature: GHK-Cu on skin and wound repair, and BPC-157 and TB-500 on tissue repair in animals. A 2026 rat study of BPC-157 and TB-500 together found no added benefit over either alone. No study of GHK-Cu combined with the other two was found in PubMed or ClinicalTrials.gov.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Component (analog evidence) — GHK-Cu: randomised trial on CO2 laser-resurfaced skin (Miller et al., 2006)Clinical trial · Randomised controlled trial of a topical product containing one componentStudied an analog, not Glow (GHK-Cu / BPC-157 / TB-500) itself | Patients after circumoral CO2 laser skin resurfacing (13 completed) | Not quantified — skin care products containing the copper tripeptide complex | Topical | Per post-treatment skin care regimen | 12 weeks of follow-up | No significant difference in erythema, wrinkles or skin quality on objective or blinded evaluation; patient-rated satisfaction was higher with GHK-Cu | Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. |
| Component (analog evidence) — BPC-157: NCT07437547, phase 2, recruiting, no resultsClinical trial · Registered phase 2 placebo-controlled trial of one component aloneStudied an analog, not Glow (GHK-Cu / BPC-157 / TB-500) itself | Adults with acute hamstring muscle strain (planned n=120) | Not disclosed in the registry record (BPC-157 alone, not a blend) | Subcutaneous | Once daily | 14 days | Hamstring muscle strain repair; no results posted | NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair |
| Component (analog evidence) — TB-500: NCT07487363, phase 1/2, recruiting, no resultsClinical trial · Registered phase 1/2 placebo-controlled trial of one component aloneStudied an analog, not Glow (GHK-Cu / BPC-157 / TB-500) itself | Adults with stable atherosclerotic cardiovascular disease (planned n=80) | Not disclosed in the registry record (TB-500 alone, not a blend) | Not disclosed | — | — | Cardiovascular biomarkers; no results posted | NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD |
| BPC-157 and TB-500 together — rat Achilles tendon repair (Biçer et al., 2026)Preclinical · Randomised preclinical study comparing each peptide alone and the two combined | Male Sprague-Dawley rats after Achilles tendon transection and repair (n=32, 8 per group) | BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both; model-specific and not convertible to a human dose | Intraperitoneal | Daily | 4 weeks | Both peptides alone improved tendon histology, and TB-500 alone improved load to failure; the combination gave no added benefit over either alone | Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. |
Where sources disagree
- A blend's amount of any one component is not a dose that was studied for that compound. See the GHK-Cu, BPC-157 and TB-500 profiles for what each component's evidence shows.
- Shop listings sell Glow as one total amount, most often 70 mg; where the split is given it is usually 50 mg GHK-Cu and 10 mg each of BPC-157 and TB-500, but the split is set by the seller, and some listings name thymosin beta-4 rather than TB-500.
- GHK-Cu's human evidence is for skin care products applied to the skin, not injection. A cream's content is not an injectable dose.
- Products named Glow are also sold as capsules, sprays and skin care. Nothing on this page applies to those forms.
Reconstitution
Common research vial sizes: 70 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 70 mg | 5 mL | 14 mg/mL of total blend | 140 mcg of total blend per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- 5 mL BAC for 70 mg blend
- Injection Sites
- Midsection
- Concentration Example
- 70 mg / 5 mL = 14 mg/mL
- Timing Notes
- Morning
- Expected Onset
- 1-2 weeks
How to reconstitute Glow (GHK-Cu / BPC-157 / TB-500)
- Check the vial size and diluent volume. The profile example for Glow (GHK-Cu / BPC-157 / TB-500) is: 5 mL BAC for 70 mg blend.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 70 mg / 5 mL = 14 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Open the peptide calculator with the Glow (GHK-Cu / BPC-157 / TB-500) preset →
Sequence & molecular data
| Amino acid sequence | GHK-Cu: Gly-His-Lys-Cu; BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (thymosin β4 17–23 fragment, as TB-500 is usually sold; some vendors supply full-length thymosin β4) |
|---|---|
| Molecular formula | Varies |
| Molecular weight | Varies |
| Half-life | Varies by component |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Glow is a compounded blend rather than a single compound, combining GHK-Cu, BPC-157 and TB-500. Each component has its own proposed mechanism: GHK-Cu binds copper and modulates matrix metalloproteinase expression and collagen synthesis in skin models; BPC-157 has been reported in animal work to promote angiogenesis through VEGFR2 and FAK signalling and to modulate the nitric oxide system; TB-500 corresponds to the actin-binding region of thymosin beta-4 and is associated with cell migration and wound closure in preclinical models. The blend has no mechanism of its own beyond those, and no controlled trial has evaluated the combination as a product. Component interactions and relative dosing are not characterised.
Origin
Commercial multi-peptide blend.
Targets
Studies
- Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? (component evidence (ghk-cu (copper peptide)))
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (component evidence (ghk-cu (copper peptide)))
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review (component evidence (bpc-157))
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (component evidence (bpc-157))
Regulatory & research status
Glow (GHK-Cu / BPC-157 / TB-500) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Glow (GHK-Cu / BPC-157 / TB-500) side effects
Glow (GHK-Cu / BPC-157 / TB-500) has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Irritation
- Headache
Contraindications
- Copper allergy
Stacking
Common stacking partners
Combinations that include Glow (GHK-Cu / BPC-157 / TB-500), with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Glow (GHK-Cu / BPC-157 / TB-500): frequently asked questions
What is Glow (GHK-Cu / BPC-157 / TB-500)?
Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them.
How does Glow (GHK-Cu / BPC-157 / TB-500) work?
Glow is a compounded blend rather than a single compound, combining GHK-Cu, BPC-157 and TB-500. Each component has its own proposed mechanism: GHK-Cu binds copper and modulates matrix metalloproteinase expression and collagen synthesis in skin models; BPC-157 has been reported in animal work to promote angiogenesis through VEGFR2 and FAK signalling and to modulate the nitric oxide system; TB-500 corresponds to the actin-binding region of thymosin beta-4 and is associated with cell migration and wound closure in preclinical models.
Is Glow (GHK-Cu / BPC-157 / TB-500) FDA approved?
No. Glow (GHK-Cu / BPC-157 / TB-500) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Glow (GHK-Cu / BPC-157 / TB-500)?
Reported half-life for Glow (GHK-Cu / BPC-157 / TB-500) is Varies by component. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Glow (GHK-Cu / BPC-157 / TB-500)?
Glow is a blend, not a single peptide. Its components are GHK-Cu (Gly-His-Lys copper complex), BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500, which is usually the acetylated thymosin β4 fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln rather than the full 43-residue protein. There is no single molecular formula; composition depends on the vial.
What peptides are similar to Glow (GHK-Cu / BPC-157 / TB-500)?
Compounds most often compared with Glow (GHK-Cu / BPC-157 / TB-500) include GHK-Cu (Copper Peptide), BPC-157, TB-500 (Thymosin Beta-4 fragment) and KLOW (GHK-Cu / KPV / BPC-157 / TB-500). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- Component evidence (GHK-Cu (Copper Peptide)) — Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?External reference
- Component evidence (GHK-Cu (Copper Peptide)) — Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataExternal reference
- Component evidence (BPC-157) — Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent ReviewExternal reference
- Component evidence (BPC-157) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewExternal reference
Related research, comparisons & guides
- KLOW vs GLOW: What Adding KPV Changes, and What It Does Not
- Peptides for Skin: Where the Evidence Is Actually Topical
- GLOW Peptide Blend: What Is Actually in the Vial
- KLOW Peptide Blend: GLOW Plus KPV, and What That Addition Changes
- The Wolverine Stack: What It Is and Where the Name Came From
- BPC-157 and TB-500: Why Blended Vials Break the Usual Math
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Glow (GHK-Cu / BPC-157 / TB-500) preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Glow (GHK-Cu / BPC-157 / TB-500) profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Glow (GHK-Cu / BPC-157 / TB-500) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →